BioCentury
ARTICLE | Finance

Ebb & Flow

October 19, 2009 7:00 AM UTC

Armed with two Special Protocol Agreements from FDA, Amarin Corp.(NASDAQ:AMRN) has been able to resurrect its fortunes by convincing investors that a compound that disappointed in its original indication of Huntington's disease deserves a second chance.

Last week, Amarin raised $70 million in an oversubscribed VIPE. The money will allow it to run two Phase III trials of AMR101 ethyl-eicosapentaenoic acid (ethyl-EPA) in patients with very high triglyceride levels and mixed dyslipidemia through to an NDA filing...